Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA meeting provides boost for BioDelivery Sciences
The FDA informed the company in February 2006 that it would not approve the drug, but the recent meeting has given the company hope that a path to
The FDA informed the company in February 2006 that it would not approve the drug, but the recent meeting has given the company hope that a path to
Gardasil is designed to prevent the majority of human papillomavirus (HPV)-related clinical diseases, those caused by HPV 6, 11, 16 and 18. HPV types 16 and 18 account
Orphan drug designation entitles Hana Biosciences to seven years of market exclusivity for ropidoxuridine in the treatment of malignant glioma. Additional incentives include tax credits related to clinical
The phase II clinical trials will be conducted in cancer centers in the US and Europe. These studies will include patients with ovarian cancer who are experiencing their
The company’s chief executive David Brennan said that the company plans to strengthen its pipeline, weakened by a string of product failures, through improving the productivity of its
Under terms of the agreement, unanimously approved by both companies’ boards of directors, TorreyPines stockholders would own approximately 58% of the combined company and Axonyx stockholders would own
Remicade was developed by Johnson & Johnson unit Centocor but is distributed in Canada by Schering-Plough’s Canadian subsidiary. Research has shown that the majority of patients treated with
The primary purposes of this clinical trial were to assess the safety and tolerability of DN-101 in combination with Sanofi-Aventis’ Taxotere (docetaxel) and to evaluate the objective tumor
PHX1149 is a potent and selective inhibitor of DPP4, a serine protease that has emerged as an important target for the treatment of type 2 diabetes. Inhibiting DPP4
Hollis-Eden’s goal in this trial will be to establish the safety of Neumune in this population, and to help identify the optimal patient subsets for further study in